SCOPE FLUIDICS SA ZY-10 (S84) - Net Assets
Based on the latest financial reports, SCOPE FLUIDICS SA ZY-10 (S84) has net assets worth €162.43 Million EUR (≈ $189.90 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€195.94 Million ≈ $229.07 Million USD) and total liabilities (€33.50 Million ≈ $39.17 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of SCOPE FLUIDICS SA ZY-10 to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €162.43 Million |
| % of Total Assets | 82.9% |
| Annual Growth Rate | 121.58% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2094.93 |
SCOPE FLUIDICS SA ZY-10 - Net Assets Trend (2021–2025)
This chart illustrates how SCOPE FLUIDICS SA ZY-10's net assets have evolved over time, based on quarterly financial data. Also explore S84 total asset value for the complete picture of this company's asset base.
Annual Net Assets for SCOPE FLUIDICS SA ZY-10 (2021–2025)
The table below shows the annual net assets of SCOPE FLUIDICS SA ZY-10 from 2021 to 2025. For live valuation and market cap data, see SCOPE FLUIDICS SA ZY-10 market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €162.43 Million ≈ $189.90 Million |
+10.99% |
| 2024-12-31 | €146.35 Million ≈ $171.10 Million |
+80.84% |
| 2023-12-31 | €80.93 Million ≈ $94.62 Million |
-75.69% |
| 2022-12-31 | €332.97 Million ≈ $389.28 Million |
+4841.72% |
| 2021-12-31 | €6.74 Million ≈ $7.88 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SCOPE FLUIDICS SA ZY-10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6179200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €4.53 Million | 2.79% |
| Other Components | €157.90 Million | 97.21% |
| Total Equity | €162.43 Million | 100.00% |
SCOPE FLUIDICS SA ZY-10 Competitors by Market Cap
The table below lists competitors of SCOPE FLUIDICS SA ZY-10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Imaflex Inc
V:IFX
|
$88.17 Million |
|
Cheer Time Enterprise Co Ltd
TW:3229
|
$88.17 Million |
|
PS Tec. Co. Ltd
KQ:002230
|
$88.19 Million |
|
Max India Limited
NSE:MAXIND
|
$88.22 Million |
|
Highland Copper Company Inc.
V:HI
|
$88.11 Million |
|
Alcadon Group AB
ST:ALCA
|
$88.10 Million |
|
Krystal Integrated Services Ltd
NSE:KRYSTAL
|
$88.08 Million |
|
Chainqui Construction Development Co Ltd
TW:2509
|
$88.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SCOPE FLUIDICS SA ZY-10's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 146,351,000 to 162,431,000, a change of 16,080,000 (11.0%).
- Net loss of 46,364,000 reduced equity.
- New share issuances of 62,273,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-46.36 Million | -28.54% |
| Share Issuances | €62.27 Million | +38.34% |
| Other Changes | €171.00K | +0.11% |
| Total Change | €- | 10.99% |
Book Value vs Market Value Analysis
This analysis compares SCOPE FLUIDICS SA ZY-10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.46x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 9.49x to 0.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.51 | €23.80 | x |
| 2022-12-31 | €122.15 | €23.80 | x |
| 2023-12-31 | €29.69 | €23.80 | x |
| 2024-12-31 | €53.69 | €23.80 | x |
| 2025-12-31 | €51.27 | €23.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SCOPE FLUIDICS SA ZY-10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -46364.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.21x
- Recent ROE (-28.54%) is above the historical average (-31.66%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -246.88% | 0.00% | 0.00x | 7.83x | €-17.31 Million |
| 2022 | 95.65% | 78833.91% | 0.00x | 1.04x | €285.19 Million |
| 2023 | -23.21% | -3640.50% | 0.01x | 1.25x | €-26.88 Million |
| 2024 | 44.70% | 49939.69% | 0.00x | 1.18x | €50.79 Million |
| 2025 | -28.54% | -46364.00% | 0.00x | 1.21x | €-62.61 Million |
Industry Comparison
This section compares SCOPE FLUIDICS SA ZY-10's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $3,395,410,609
- Average return on equity (ROE) among peers: -67.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SCOPE FLUIDICS SA ZY-10 (S84) | €162.43 Million | -246.88% | 0.21x | $88.16 Million |
| IZOTROPIC CORP. (1R3) | $-4.86 Million | 0.00% | 0.00x | $11.45 Million |
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | $10.41 Million | -90.99% | 0.83x | $1.06 Million |
| HANGZHOU TIGERMED CO. H 1 (5HZ1) | $24.45 Billion | 8.28% | 0.21x | $500.93 Million |
| Check-Cap Ltd (7CC) | $50.69 Million | -33.94% | 0.10x | $8.64 Million |
| INTERGRATED DIA.H DL 025 (8I8) | $3.10 Billion | 16.46% | 0.86x | $288.34 Million |
| GENETIC ANALYSIS NK -60 (8V8) | $27.08 Million | -42.15% | 0.94x | $2.85 Million |
| GENINCODE PLC LS -01 (9PL) | $1.29 Million | -544.30% | 2.25x | $6.89 Million |
| INOVIQ LTD. (EGQ0) | $19.99 Million | -32.79% | 0.09x | $25.34 Million |
| Eurofins Scientific SE (ESF0) | $4.68 Billion | 16.73% | 1.00x | $11.18 Billion |
| ICON Public Limited Company (IJF) | $1.62 Billion | 23.11% | 0.80x | $7.52 Billion |
About SCOPE FLUIDICS SA ZY-10
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.